NewsBenzingaOKYO Pharma annonce l’inclusion des premiers patients dans l’essai de phase 3 NEPTUNE d’ursosimod pour la douleur cornéenne neuropathique OKYO Pharma annonce l’inclusion des premiers patients dans l’essai de phase 3 NEPTUNE d’ursosimod pour la douleur cornéenne neuropathique Benzinga 2026.10.06 11:05 (GMT+0) Open on Benzinga Other news Important News from Last Night and This Morning (October 19–October 20) Stock Pickers Burned by the AI Boom Think Their Moment Has Finally Arrived Walmart’s Flipkart is quietly building a food delivery challenger in India Robotics AI Company Dream Labs Completes $90 Million Seed Round, Launches Robot Foundation Model API Elysium, an L2 network in the Hyperliquid ecosystem, to launch mainnet on November 9 ARK Invest buys about $8.1 million of CoreWeave stock, sells about $3.56 million of Palantir stock
